Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01327651 · ClinicalTrials.gov registry record · Phase 2
The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
A Phase 2 study, sponsored by HIV Prevention Trials Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 622
- Enrollment target
NCT01327651 is a Phase 2 study that has completed, run by HIV Prevention Trials Network. The registered enrollment target is 622 participants.
The verdict
NCT01327651, a Phase 2 study, has completed, sponsored by HIV Prevention Trials Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 622 participants
- Enrollment target
Study Summary
Pre-exposure prophylaxis (PrEP) is a method of preventing HIV infection through the use of antiretroviral (ARV) medications before exposure to HIV. This study will examine the feasibility of different methods of dosing for a PrEP regimen. Three methods of delivery will be compared: daily, time-based, and event-based.
Interventions
- DRUG Daily dosing
- DRUG Time-driven dosing
- DRUG Event-driven dosing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 622 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01327651
The ClinicalTrials.gov registry entry for NCT01327651 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 622 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HIV Prevention Trials Network, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Daily dosing is the first listed.
NCT01327651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01327651 about?
NCT01327651 is a clinical study titled "The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)". Pre-exposure prophylaxis (PrEP) is a method of preventing HIV infection through the use of antiretroviral (ARV) medications before exposure to HIV. This study will examine the feasibility of different methods of dosing for a PrEP regimen. Three methods of delivery will be compared: daily, time-based...
What is the current status of trial NCT01327651?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 622 participants. The study started on 2011-08. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01327651?
The interventions under investigation include: Daily dosing (DRUG), Time-driven dosing (DRUG), Event-driven dosing (DRUG).
Who is sponsoring clinical trial NCT01327651?
This trial is sponsored by HIV Prevention Trials Network, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.